Company research
Obsidian Therapeutics, Inc.
CIK 2130606Updated Nov 13, 2026
SecurityOBX · NASDAQ · equity
Name history
Gazelle Parent, Inc. · through Aug 3, 2026
OBX price & chart
Loading TradingView…
NASDAQ:OBX on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte, or TIL, cell therapies for the treatment of patients with solid tumors. Our proprietary cytoDRiVE™ platform is highly versatile and allows us to leverage drug responsive domains, or DRDs, to control protein function, with our initial focus on TIL cell therapies developed from this platform, or cytoTILs™. Our lead product candidate, amsoki-cel (formerly, “OBX-115”), is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of advanced melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer, or NSCLC. Our proprietary cytoDRiVE platform has enabled amsoki-cel to have the potential to drive superior tumor-killing activity with a significantly more tolerable safety profile. In contrast to other TIL approaches, amsoki-cel is designed with regulatable membrane-bound IL15, or mbIL15, which drives TIL persistence, eliminates the need to dose toxic interleukin-2, or IL2, and enables outpatient administration of low-dose lymphodepletion. We currently own …
In the news
No coverage from other publishers is available.
Recent filings
424B3 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by Paradigm Biocapital Advisors LP regarding Obsidian Therapeutics, Inc.
EFFECT filing
Show 5 more recent filings
Offerings
Registration 333-298642
Registration 333-295249
Filing attachments
d20599dex991.htm · 8-K · 2026-11-12
Exhibit 99.1 Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Presented positive updated efficacy and pooled safety data on amsoki-cel in advanced melanoma at the 41st Annual SITC Meeting, including a 67% ORR (n=10/15), median PFS of 8.3 months and median DOR not yet reached at 14.3 months median study follow-up Enrollment is ongoing in registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study, with topline data expected by year-end…
Read attachment ↗tm2626606d1_ex99-1.htm · SCHEDULE 13G · 2026-10-05
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Shares, par value $0.0001 per share, of Obsidian Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned here…
Read attachment ↗obx-ex99_1.htm · 8-K/A · 2026-08-14
Exhibit 99.1 OBSIDIAN THERAPEUTICS SUB, INC. (F/K/A OBSIDIAN THERAPEUTICS, INC.) CONDENSED CONSOLIDATED BALANCE SHEETS (AMOUNTS IN THOUSANDS, EXCEPT FOR SHARE DATA) (UNAUDITED) June 30, December 31, …
Read attachment ↗obx-ex99_2.htm · 8-K/A · 2026-08-14
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Unless the context otherwise requires, references in this exhibit to “we,” “us,” “our” and the “Company” refer to Obsidian Therapeutics Sub, Inc. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements as of June 30, 2026, and for the six months ended June 30, 2026 and …
Read attachment ↗d105773dex991.htm · S-8 · 2026-08-03
Exhibit 99.1 OBSIDIAN THERAPEUTICS, INC. 2016 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Obsidian Therapeutics, Inc. 2016 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Obsidian Therapeutics, Inc., a Delaware corporation (including any successor entity, the “Company”) and its Subsidiaries, upon whose judgment, …
Read attachment ↗d105773dex992.htm · S-8 · 2026-08-03
Exhibit 99.2 OBSIDIAN THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Obsidian Therapeutics, Inc. 2026 Equity Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Obsidian Therapeutics, Inc. (the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Company largely depe…
Read attachment ↗